Sign in Subscribe
Anti-obesity agents

Novo Nordisk Outbids Pfizer for Metsera in $6 Billion Acquisition Bid

Strategic Insights

— 1 min read

Danish pharmaceutical giant Novo Nordisk has announced an unsolicited bid to acquire obesity treatment maker Metsera, topping a previous offer from US rival Pfizer. The bid values the US biotech firm at $6 billion, with Novo Nordisk offering $56.50 per share in cash. This move comes after Pfizer's earlier offer of $47.50 per share, valuing Metsera at $4.9 billion.

Metsera has accepted Novo Nordisk's offer, citing it as "superior" under its merger agreement with Pfizer. Pfizer has reacted strongly, calling Novo Nordisk's offer a "reckless and unprecedented proposal" that attempts to suppress competition in the obesity treatment market.

Key Takeaways:

  • Novo Nordisk's bid for Metsera is valued at $6 billion, with an offer of $56.50 per share in cash.
  • The bid is currently subject to review by Metsera's board of directors.
  • Pfizer had previously offered to acquire Metsera for $4.9 billion, with an offer of $47.50 per share.
  • Novo Nordisk's acquisition would give the company complementary portfolio and capabilities, with a focus on maximising the potential of Metsera's treatments.
  • The acquisition is particularly vying for MET-097i, Metsera's most advanced treatment, currently in phase 2 clinical trials.
  • Shares in Novo Nordisk were down over two percent on the Copenhagen stock exchange following the announcement.
  • Novo Nordisk has recently faced competition from rival treatments in its key market, the United States, notably with US giant Eli Lilly's Zepbound.
  • Pfizer had a hugely profitable breakthrough as it was one of the first companies to develop a Covid vaccine, but its stock price has fallen since the pandemic ended.

Statistics:

  • Novo Nordisk's bid for Metsera is valued at $6 billion.
  • Pfizer's previous offer valued Metsera at $4.9 billion.
  • Novo Nordisk's offer is $56.50 per share, compared to Pfizer's $47.50 per share.
  • The acquisition would give Novo Nordisk a new treatment option in the form of MET-097i, a GLP-1 receptor agonist.
  • Novo Nordisk's shares have been down over two percent on the Copenhagen stock exchange following the announcement.

Sources:

  • "Novo Nordisk makes $6 billion bid for Metsera". doc.afp.com.

Read more